Unitaid is a hosted partnership of the World Health Organization (WHO) that invests in new ways to prevent, diagnose and treat HIV/AIDS, tuberculosis and malaria more quickly, more cheaply and more effectively

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Dr. Susan Desmond-Hellmann and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.

TB REACH is a multi-lateral funding mechanism primarily supported by Global Affairs Canada, with additional funding from the Bill and Melinda Gates Foundation. The Indonesia Health Fund has also made a pledge to support TB REACH’s Indonesian effort. TB REACH provides grants to partners for testing innovative approaches and technologies aimed at increasing the number of people diagnosed and treated for TB, decreasing the time to appropriate treatment and improving treatment success rates. It combines fast-track, results-based financing and rigorous, external monitoring and evaluation (M&E) to produce results, so other donor agencies and/or national governments can scale-up successful approaches and maximize their own investments

Founded in 2002, the Global Fund is a partnership between governments, civil society, the private sector and people affected by the diseases. The Global Fund raises and invests nearly US$4 billion a year to support programs run by local experts in countries and communities most in need.

The U.S. Agency for International Development leads the U.S. Government's international development and disaster assistance through partnerships and investments that save lives, reduce poverty, strengthen democratic governance, and help people emerge from humanitarian crises and progress beyond assistance

FIND (Foundation for Innovative New Diagnostics) is an international non-profit organization that enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola

The Stop TB Partnership is leading the way to a world without tuberculosis (TB), a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership's mission is to serve every person who is vulnerable to TB and ensure that high-quality diagnosis, treatment and care is available to all who need it. They operate through a secretariat hosted by UNOPS in Geneva, Switzerland and seven working groups whose role is to accelerate progress on access to TB diagnosis and treatment; research and development for new TB diagnostics, drugs and vaccines; and tackling drug resistant- and HIV-associated TB. The secretariat is governed by a Coordinating Board that sets strategic direction for the global fight against TB. The Partnership is recognized as a unique international body with the power to align actors all over the world in the fight against TB. The participation of a wide range of constituencies gives us credibility and the broad range of medical, social and financial expertises needed to defeat TB.

TB REACH is a multi-lateral funding mechanism primarily supported by Global Affairs Canada, with additional funding from the Bill and Melinda Gates Foundation. The Indonesia Health Fund has also made a pledge to support TB REACH’s Indonesian effort. TB REACH provides grants to partners for testing innovative approaches and technologies aimed at increasing the number of people diagnosed and treated for TB, decreasing the time to appropriate treatment and improving treatment success rates. It combines fast-track, results-based financing and rigorous, external monitoring and evaluation (M&E) to produce results, so other donor agencies and/or national governments can scale-up successful approaches and maximize their own investments

The U.S. Agency for International Development leads the U.S. Government's international development and disaster assistance through partnerships and investments that save lives, reduce poverty, strengthen democratic governance, and help people emerge from humanitarian crises and progress beyond assistance

The New Diagnostics Working Group (NDWG) is one of the seven working groups of the Stop TB Partnership. It supports the Partnership in its goal of eliminating tuberculosis (TB), in particular by promoting the development and evaluation of new TB diagnostic tools. The NDWG is a network of experts representing stakeholders from academia, NGOs, multilaterals and governmental institutions, TB high-burden countries, industry, and the patient community

The Global Laboratory Initiative (GLI) is a network of international partners dedicated to accelerating and expanding access to quality assured laboratory services in response to the diagnostic challenges of TB, notably HIV-associated and drug-resistant TB. The GLI provides a focus for TB within the framework of a multi-faceted yet integrated approach to laboratory capacity strengthening.

EurolacTB is a consortium aimed at promoting and strengthening research collaboration between European and Latin American scientists in the area of tuberculosis.

The McGill International TB Centre, situated at the McGill University Health Centre in Montreal, Canada, is a world leader in the interdisciplinary study of TB, bringing together researchers in biomedical, clinical, epidemiological and social determinants of TB and other mycobacterial diseases.

Prof. Madhukar Pai, MD, PhD is a Canada Research Chair in Epidemiology & Global Health at McGill University, Montreal. He is the Director of McGill Global Health Programs, and Associate Director of the McGill International TB Centre. Madhu’s research is mainly focused on improving the diagnosis and treatment of tuberculosis, especially in high-burden countries like India and South Africa. His research is supported by grant funding from the Gates Foundation, Grand Challenges Canada, and Canadian Institutes of Health Research. He has more than 300 publications. He is recipient of the Union Scientific Prize, Chanchlani Global Health Research Award, and Haile T. Debas Prize. He is a member of the Royal Society of Canada.

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.

The World Health Organization is a specialized agency of the United Nations established in 1948 to further international cooperation for improved public health conditions. The WHO Global TB Programme is responsible for coordinating WHO's global efforts to end TB

The Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of food supply, cosmetics, and products that emit radiation.

The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in London. It began operating in 1995. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.

In most countries, TB prevention, care and control activities are organized within a national TB programme, which is usually housed within the ministry of health; however, the programme’s activities are implemented at different levels: the central, intermediate, primary health-care and peripheral levels

The Global Drug Facility has changed the landscape of TB care since its creation in 2001 by increasing access to high quality and affordable TB treatments & diagnostics to population in need. In 2014, the GDF has delivered more than 24 million treatment courses to 133 countries. GDF is today the largest supplier of quality assured patient treatments (first line drugs, second line drugs and paediatric forms) worldwide in the public sector. GDF is a unique TB medicines procurement mechanism, also providing technical assistance and innovative tools to countries, and supporting key projects like TB REACH, Expand TB, TB Expert in the diagnostic field.